715
Views
22
CrossRef citations to date
0
Altmetric
Original Investigation

Familial abnormalities of endocannabinoid signaling in schizophrenia

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 117-125 | Received 02 Aug 2017, Accepted 22 Feb 2018, Published online: 22 Mar 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Ruhan Deniz Topuz, Yasemin Gorgulu & Milkibar Kyazim Uluturk. (2023) Could serum endocannabinoid and N-acylethanolamine levels be important in bipolar disorder?. The World Journal of Biological Psychiatry 24:4, pages 314-320.
Read now
Deepak Cyril D’Souza, Marta DiForti, Suhas Ganesh, Tony P. George, Wayne Hall, Carsten Hjorthøj, Oliver Howes, Matcheri Keshavan, Robin M. Murray, Timothy B Nguyen, Godfrey D. Pearlson, Mohini Ranganathan, Alex Selloni, Nadia Solowij & Edoardo Spinazzola. (2022) Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. The World Journal of Biological Psychiatry 23:10, pages 719-742.
Read now

Articles from other publishers (19)

Helena K. Kim, Vanessa F. Gonçalves, Muhammad I. Husain, Daniel J. Müller, Benoit H. Mulsant, Gwyneth Zai & Stefan Kloiber. (2023) Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia. Psychiatry Research 330, pages 115563.
Crossref
Riccardo Bortoletto, Fabiana Piscitelli, Anna Candolo, Sagnik Bhattacharyya, Matteo Balestrieri & Marco Colizzi. (2023) Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence. Frontiers in Psychiatry 14.
Crossref
Gregory H. Jones, Omar F. Pinjari, Courtney M. Vecera, Kacy Smith, Anita Barrera & Rodrigo Machado-Vieira. (2023) The Role of the Gut Microbiome in Bipolar Disorder and its Common Medical Comorbidities. Frontiers in Neuroendocrinology 70, pages 101078.
Crossref
Anahita Bassir Nia, Claire L Gibson, Sharron A Spriggs, Samantha E Jankowski, Daniel DeFrancisco, Amy Swift, Charles Perkel, Igor Galynker, Chandrashekhar Honrao, Alexandros Makriyannis & Yasmin L Hurd. (2023) Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. Journal of Psychopharmacology 37:5, pages 484-489.
Crossref
Jocelyne Alcaraz-Silva, Daniel Feingold, Gerardo Viana-Torre, Henning Budde, Claudio Imperatori, Sérgio Machado & Eric Murillo-Rodríguez. (2023) The Endocannabinoid System as a Biomarker for Diagnostic and Therapeutic Applications in Depression and Anxiety. CNS & Neurological Disorders - Drug Targets 22:3, pages 417-430.
Crossref
Bruno M. Fonseca, Niloy Bhowmick, Sara Cunha, João Maia, Georgina Correia-da-Silva, Natércia Teixeira & Susana I. Sá. (2023) Long-Term Tamoxifen Effects in the Cyclic Interaction of the Endocannabinoid and Endocrine System in the Rat Central Nervous System. Biomedicines 11:3, pages 720.
Crossref
Anahita Salehi, Parsa Namaei, Fateme TaghaviZanjani, Sayna Bagheri, Kamyar Moradi, Mohammad-Reza Khodaei Ardakani & Shahin Akhondzadeh. (2022) Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. Psychiatry Research 316, pages 114737.
Crossref
Timothy A. Couttas, Beverly Jieu, Cathrin Rohleder & F. Markus Leweke. (2022) Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review. Frontiers in Psychiatry 13.
Crossref
Brandon Gunasekera, Kelly Diederen & Sagnik Bhattacharyya. (2021) Cannabinoids, reward processing, and psychosis. Psychopharmacology 239:5, pages 1157-1177.
Crossref
Daniela Navarro, Ani Gasparyan, Francisco Navarrete, Abraham B. Torregrosa, Gabriel Rubio, Marta Marín-Mayor, Gabriela B. Acosta, Maria Salud Garcia-Gutiérrez & Jorge Manzanares. (2022) Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders. International Journal of Molecular Sciences 23:9, pages 4764.
Crossref
Helena P. G. Joaquim, Alana C. Costa, Cícero A. C. Pereira, Leda L. Talib, Martinus M. V. Bilt, Alexandre A. Loch & Wagner F. Gattaz. (2021) Plasmatic endocannabinoids are decreased in subjects with ultra‐high risk of psychosis. European Journal of Neuroscience 55:4, pages 1079-1087.
Crossref
Tomasz Bielawski, Lucas Albrechet-Souza & Dorota Frydecka. (2021) Endocannabinoid system in trauma and psychosis: distant guardian of mental stability. Reviews in the Neurosciences 32:7, pages 707-722.
Crossref
K.M. Bermingham, L. Brennan, R. Segurado, I.J. Gray, R.E. Barron, E.R. Gibney, M.F. Ryan, M.J. Gibney, J.W. Newman & Dr. A.M. O'Sullivan. (2021) Genetic and environmental influences on serum oxylipins, endocannabinoids, bile acids and steroids. Prostaglandins, Leukotrienes and Essential Fatty Acids 173, pages 102338.
Crossref
Yinyan Fan, Quanxi Gan, Huibin Feng & Lixue Yuan. (2021) Comparison and Analysis of EEG with Negative and Positive Symptoms of Schizophrenia. Journal of Medical Imaging and Health Informatics 11:3, pages 921-929.
Crossref
Ranjini Garani, Jeremy J. Watts & Romina Mizrahi. (2021) Endocannabinoid system in psychotic and mood disorders, a review of human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry 106, pages 110096.
Crossref
Francisco Navarrete, María Salud García-Gutiérrez, Rosa Jurado-Barba, Gabriel Rubio, Ani Gasparyan, Amaya Austrich-Olivares & Jorge Manzanares. (2020) Endocannabinoid System Components as Potential Biomarkers in Psychiatry. Frontiers in Psychiatry 11.
Crossref
Camila Marchioni, Israel Donizeti de Souza, Vinicius Ricardo AcquaroJuniorJunior, José Alexandre de Souza Crippa, Vitor Tumas & Maria Eugênia Costa Queiroz. (2018) Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases. Analytica Chimica Acta 1044, pages 12-28.
Crossref
Gabriela Seabra, Ana Caroline B. Falvella, Paul C. Guest, Daniel Martins-de-Souza & Valéria de Almeida. (2018) Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. PROTEOMICS 18:18, pages 1700270.
Crossref
F. Markus Leweke, Juliane K. Mueller, Bettina Lange, Stefan Fritze, Cristina E. Topor, Dagmar Koethe & Cathrin Rohleder. (2018) Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. CNS Drugs 32:7, pages 605-619.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.